Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

European Urology Open Science, (19), p. e1173-e1174, 2020

Journal article published in 2020 by J. L. Boormans, R. De Wit, G. S. Kulkarni, E. M. Uchio, M. Roumiguié, L. E. M. Krieger, E. A. Singer, A. M. Kamat, P. Grivas, H. K. Seo, H. Nishiyama, B. R. Konethy, T. Saretsky, H. Li, K. Nam and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving forbidden

Published version: archiving forbidden

Policy details

Data provided by